CYCC
Cyclacel Pharmaceuticals Inc
$
9.280
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
9.450
Open
9.010
VWAP
9.15
Vol
86.07K
Mkt Cap
14.70M
Low
8.950
Amount
787.14K
EV/EBITDA(TTM)
--
Total Shares
1.46M
EV
10.89M
EV/OCF(TTM)
--
P/S(TTM)
301.46
Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing cancer medicines based on cell cycle, epigenetics and mitosis biology. Its epigenetic/anti-mitotic program is evaluating plogo, a Polo-like kinase 1 (PLK1) inhibitor, in solid tumors and hematological malignancies. PLK1 is a serine/threonine kinase with a central role in cell division, or the mitotic phase of the cell cycle, and is a regulator of the DNA damage checkpoint. The Company’s plogo is a novel, small-molecule, selective and potent PLK1 inhibitor, which has demonstrated potent and selective target inhibition (PLK1 IC50 approximately 3 nM) and efficacy in human tumor xenografts at non-toxic doses. Its translational biology program supports the development of plogo in solid tumor and hematological malignancy indications. PLK1 over-expressing tumors include colorectal, esophageal, gastric, leukemia, lung, lymphoma, ovarian and squamous cell cancers.
Show More
Get winning stock picks in minutes
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2024Q4
FY2025Q1
FY2025Q2
10.00K
-67.74%
-69.600
-30.18%
25.00K
-13.79%
-69.600
-87.22%
25.00K
+525%
-72.000
-58.33%
Estimates Revision
The market is revising No Change the revenue expectations for Cyclacel Pharmaceuticals, Inc. (CYCC) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -77.50%.
Revenue Estimates for FY2025
No Change
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
0.00%
In Past 3 Month
Stock Price
Go Down
-77.50%
In Past 3 Month
Get winning stock picks in minutes
Valuation Metrics
The current forward P/E ratio for Cyclacel Pharmaceuticals Inc (CYCC.O) is -0.03, compared to its 5-year average forward P/E of -1.02. For a more detailed relative valuation and DCF analysis to assess Cyclacel Pharmaceuticals Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-1.02
Current PE
-0.03
Overvalued PE
-0.10
Undervalued PE
-1.93
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
50.77
Current PS
139.07
Overvalued PS
193.52
Undervalued PS
-91.99
Financials
Annual
Quarterly
FY2025Q1
YoY :
-100.00%
0.00
Total Revenue
FY2025Q1
YoY :
+15.64%
-5.04M
Operating Profit
FY2025Q1
YoY :
-97.25%
-81.00K
Net Income after Tax
FY2025Q1
YoY :
-99.98%
-0.09
EPS - Diluted
FY2025Q1
YoY :
-100.00%
N/A
Free Cash Flow
FY2025Q1
YoY :
-100.00%
N/A
Gross Profit Margin - %
FY2025Q1
YoY :
-100.00%
N/A
FCF Margin - %
FY2025Q1
YoY :
-100.00%
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
83.4K
USD
1
3-6
Months
0.0
USD
0
6-9
Months
5.5M
USD
1
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
83.4K
USD
1
3-6
Months
0.0
USD
0
6-9
Months
5.5M
USD
1
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
CYCC News & Events
Events Timeline
2025-07-16 (ET)
2025-07-16
09:02:25
Cyclacel 'not aware of any material developments' amid stock price volatility
2025-07-07 (ET)
2025-07-07
06:06:37
Cyclacel announces amendment to exchange agreement with Fitters
2025-07-07
06:05:03
Cyclacel announces publication of preclinical data on plogosertib
Sign Up For More Events
Sign Up For More Events
News
9.5
08-05BenzingaWhy Palantir Technologies Shares Are Trading Higher By Over 5%; Here Are 20 Stocks Moving Premarket
2.0
08-05BenzingaCyclacel Pharmaceuticals Stock Up 34.6% In Massive After-Hours Rally
9.0
08-04NewsfilterCYCLACEL PHARMACEUTICALS HIGHLIGHTS PRECLINICAL DATA SHOWING THAT CANCER OF THE BILIARY TRACT IS SENSITIVE TO PLOGOSERTIB
Sign Up For More News
People Also Watch
FAQ
What is Cyclacel Pharmaceuticals Inc (CYCC) stock price today?
The current price of CYCC is 9.28 USD — it has increased 2.54 % in the last trading day.
What is Cyclacel Pharmaceuticals Inc (CYCC)'s business?
What is the price predicton of CYCC Stock?
What is Cyclacel Pharmaceuticals Inc (CYCC)'s revenue for the last quarter?
What is Cyclacel Pharmaceuticals Inc (CYCC)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Cyclacel Pharmaceuticals Inc (CYCC)'s fundamentals?
How many employees does Cyclacel Pharmaceuticals Inc (CYCC). have?